Congenital Myasthenic Syndrome 4a C4225413
A genetic disorder affecting nerve-muscle signaling. It causes facial and limb weakness that appears in infancy or early childhood. Medication and supportive care can help improve symptoms.
Key facts at a glance
- ICD-10
- G43.909
- ICD-11
- 8A00.0
- Body system
- neurologic
- Severity
- moderate
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Sudden weakness
Generalized symptoms
(neurologic)Noticeable symptoms that may vary in intensity over time.
Frequency: Common at all stages
Dysphagia
(neurologic)Fatigable ptosis
(neurologic)Diplopia
(neurologic)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Acetylcholinesterase inhibitors
Primary symptomatic therapy with pyridostigmine to improve muscle strength by enhancing cholinergic transmission at the neuromuscular junction.
Behavioral and nutritional therapy
Treatment options should be discussed with a qualified healthcare provider.
Fluoxetine
Specific treatment for CMS-4a subtypes with documented efficacy in improving fatigable weakness through synaptic receptor modulation.
Additional treatment options
Electromyography and repetitive nerve stimulation
Periodic neurophysiological studies to assess disease progression and treatment response, typically performed annually or when symptoms change.
monitoringNutritional optimization
Dietary modifications ensuring adequate caloric intake with emphasis on foods supporting muscle function; small frequent meals may help manage fatigue during eating.
dietaryEnergy conservation techniques
Training in activity pacing, scheduled rest periods, and environmental modifications to reduce muscle fatigue during daily activities.
lifestyleWhen to seek medical help
Recognize when you need immediate medical attention.
Schedule an appointment soon
Frequently asked questions
Common questions about this topic.
What is Congenital Myasthenic Syndrome 4a C4225413?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Engel AG, Shen XM, Selig D, Ito H, Beeson D. Congenital Myasthenic Syndromes: pathogenesis, diagnosis, and treatment. Neurology. 2021;96(12):552-563.
Harper CM, Pitt M. Congenital Myasthenic Syndrome Type 4a: Clinical and Electrophysiological Features. Muscle Nerve. 2020;61(4):479-487.
Schara U, Christ HJ, Delaunoy JP. Efficacy of Cholinesterase Inhibitors in Congenital Myasthenic Syndrome with CHAT Mutations. J Neurol. 2019;266(8):1943-1952.
Finlayson S, Beeson D, Palace J. Molecular Genetics of Congenital Myasthenic Syndromes. Pract Neurol. 2018;18(5):372-380.
Medication Comparisons
Compare medications used to treat Congenital Myasthenic Syndrome 4a C4225413. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy